Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

AGENBullishIndustry Newsnews

High materiality7/10

Agenus Reports Three-Year Ovarian Cancer Data for BOT-BAL Immunotherapy

Oct 3, 2026, 11:02 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive early efficacy signals in a large ovarian cancer cohort could improve sentiment and near-term risk tolerance, though no regulatory approvals are implied.

AI summary

What happened, with direct paths to the underlying reporting

Agenus announced three-year follow-up results from its ovarian cancer cohort in the Phase 1b C-800-01 study, evaluating botensilimab with balstilimab. The data include survival outcomes analyzed by platinum-sensitivity, suggesting durability of the BOT-BAL combination in select patients. Although early-stage, the results could influence development timelines and investor perception of Agenus' immuno-oncology platform.

Agenus reports 3-year follow-up from ovarian cancer arm of C-800-01 trial.
BOT plus BAL shows potential survival signals in 400+ patient Phase 1b study.
Results include survival data and outcomes by platinum sensitivity.
Data may inform ongoing development and investor sentiment.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Agenus Reports Three-Year Ovarian Cancer Data for BOT-BAL Immunotherapy

Agenus pivots to ROBBIN, secures capital to extend runway to 2031

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang